Tranexamic Acid in Chinese Elderly Patients With Intertrochanteric Fracture RCT

• Status: Active, not recruiting
• Trial end date: 2020-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Hip fracture posed a major challenge to the health care system, with the one-year mortality of hip fracture reported as being approximately 20%. Perioperative haemoglobin level was associated with functional level of the patient and even mortality.

Different methods for administration of tranexamic acid had been described. It was well established that systemic administration of tranexamic acid could reduce perioperative blood loss and transfusion rate. Topical administration had been shown to decrease blood loss and transfusion rate.

The objective of our study is to investigate the hypothesis that tranexamic acid will reduce blood loss and transfusion rate in elderly patients undergoing hip fracture surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Adults over the age of 60

• Acute isolated intertrochanteric fracture and sub trochanteric fracture treated with short proximal femoral nailing

Exclusion Criteria:

• Use of any anticoagulant at the time of admission

• Documented allergy to tranexamic acid

• History of pulmonary embolism or deep vein thrombosis

• Hepatic failure

• Severe renal insufficiency

• Active coronary artery disease in the past 12 months

• History of cerebrovascular accident in the past 12 months

• Presence of a drug-eluting stent

• Active oncological diseases

• Coagulopathy (international normalised ratio (INR)>1.4)

• Pathological fractures

• Periprosthetic fractures

• Operation >2 days from admission